Merrimack Pharma scraps IPO

Merrimack Pharmaceuticals' attempt to buck the trend on IPOs ended in failure today. The developer, a 2011 Fierce 15 company, has 5 drugs in the clinic and reportedly scrapped its offering saying that market conditions prevented it from pushing ahead. Story

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.